Foghorn Therapeutics to Participate in the BMO Oncology Summit
Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company, has announced its participation in investor meetings at the BMO Oncology Summit on October 8, 2024, in New York, NY. The company is pioneering a new class of medicines that aim to correct abnormal gene expression to treat serious diseases.
Foghorn's Gene Traffic Control® platform and resulting broad pipeline focus initially on oncology but have the potential to address a wide spectrum of diseases. This innovative approach could potentially transform the lives of many patients suffering from various conditions.
Foghorn Therapeutics Inc. (Nasdaq: FHTX), un'azienda biotecnologica in fase clinica, ha annunciato la sua partecipazione a incontri con gli investitori al BMO Oncology Summit l'8 ottobre 2024, a New York, NY. L'azienda sta pionierando una nuova classe di farmaci che mirano a correggere l'espressione genica anomala per trattare malattie gravi.
La piattaforma Gene Traffic Control® di Foghorn e il conseguente ampio portafoglio inizialmente si concentrano sull'oncologia, ma hanno il potenziale per affrontare un ampio spettro di malattie. Questo approccio innovativo potrebbe trasformare la vita di molti pazienti affetti da varie condizioni.
Foghorn Therapeutics Inc. (Nasdaq: FHTX), una empresa de biotecnología en etapa clínica, ha anunciado su participación en reuniones con inversionistas en el BMO Oncology Summit el 8 de octubre de 2024, en Nueva York, NY. La empresa está pionera en una nueva clase de medicamentos que buscan corregir la expresión genética anormal para tratar enfermedades graves.
La plataforma Gene Traffic Control® de Foghorn y su amplio pipeline se centran inicialmente en oncología, pero tienen el potencial de abordar un amplio espectro de enfermedades. Este enfoque innovador podría transformar la vida de muchos pacientes que sufren de diversas condiciones.
포그혼 테라퓨틱스 Inc. (Nasdaq: FHTX)는 임상 단계의 바이오 기술 회사로, 2024년 10월 8일 뉴욕 NY에서 열리는 BMO Oncology Summit에서 투자자 회의에 참여한다고 발표했습니다. 이 회사는 심각한 질병을 치료하기 위해 비정상적인 유전자 발현을 교정하는 것을 목표로 하는 새로운 의약품 클래스를 개척하고 있습니다.
포그혼의 Gene Traffic Control® 플랫폼과 그로 인해 탄생한 폭넓은 파이프라인은 처음에는 종양학에 집중하지만, 광범위한 질병을 다룰 잠재력이 있습니다. 이 혁신적인 접근 방식은 다양한 질환으로 고통받는 많은 환자들의 삶을 변화시킬 수 있습니다.
Foghorn Therapeutics Inc. (Nasdaq: FHTX), une entreprise de biotechnologie en phase clinique, a annoncé sa participation à des réunions d'investisseurs lors du BMO Oncology Summit le 8 octobre 2024 à New York, NY. L'entreprise est à l'avant-garde d'une nouvelle classe de médicaments visant à corriger l'expression génique anormale pour traiter des maladies graves.
La plateforme Gene Traffic Control® de Foghorn et son large portefeuille se concentrent initialement sur l'oncologie, mais ont le potentiel d'aborder un large éventail de maladies. Cette approche innovante pourrait potentiellement transformer la vie de nombreux patients souffrant de diverses conditions.
Foghorn Therapeutics Inc. (Nasdaq: FHTX), ein Unternehmen der Biotechnologie in der klinischen Phase, hat ihre Teilnahme an Investorenmeetings auf dem BMO Oncology Summit am 8. Oktober 2024 in New York, NY, bekannt gegeben. Das Unternehmen ist Vorreiter einer neuen Klasse von Medikamenten, die darauf abzielen, abnormale Genexpression zu korrigieren, um schwere Krankheiten zu behandeln.
Die Gene Traffic Control® Plattform von Foghorn und das daraus resultierende breite Pipeline konzentrieren sich zunächst auf Onkologie, haben jedoch das Potenzial, ein breites Spektrum von Krankheiten anzugehen. Dieser innovative Ansatz könnte das Leben vieler Patienten, die unter verschiedenen Bedingungen leiden, potenziell transformieren.
- None.
- None.
CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in investor meetings at the BMO Oncology Summit being held Tuesday, October 8, 2024, in New York, NY. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
About Foghorn Therapeutics
Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information about the Company, and follow us on X and LinkedIn.
Contact:
Karin Hellsvik, Foghorn Therapeutics Inc. (Investors & Media)
khellsvik@foghorntx.com
FAQ
When and where is Foghorn Therapeutics (FHTX) participating in the BMO Oncology Summit?
What is the focus of Foghorn Therapeutics' (FHTX) Gene Traffic Control® platform?
What type of company is Foghorn Therapeutics (FHTX)?
How might Foghorn Therapeutics' (FHTX) pipeline impact patients?
